semaglutide from china price Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China's weight-loss drug makers take

The recent US approval of semaglutide for fibrotic metabolic dysfunction-associated steatohepatitis is likely to add relatively few newly eligible patients because most already qualify for treatment through existing indications for obesity or high-risk type 2 diabetes, a population-based analysis found

Over 100 million Americans watched Hims & Hers (HIMS) controversial Super Bowl ad taking on the weight-loss drug industry this Sunday during the Super Bowl.

Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes

[1] Serious gastrointestinal events were not prominently reported in the available phase 2 data, though the limited duration and sample size of phase 2 studies mean that longer-term phase 3 data will provide a more complete safety picture